Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1243290
                    [Title] => New drug helps people with advanced HER2-positive breast cancer live longer
                    [Summary] => 
Roche announced recently that trastuzumab emtansine significantly extended the time people with advanced HER2-positive breast cancer (metastatic and unresectable locally advanced/recurrent) lived without their disease worsening (progression-free survival), compared to people who received a treatment of their physician’s choice in an open-label phase III study called TH3RESA.

	 

                    [DatePublished] => 2013-10-10 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 551569
                    [Title] => Greater chances of cure for patients with breast cancer
                    [Summary] => 
Roche announced recently its new long-term follow up-data from two large pivotal studies evaluating adjuvant trastuzumab in HER2-positive early- stage breast cancer presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). 
                    [DatePublished] => 2010-02-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Freeman Cebu Lifestyle
                    [SectionUrl] => cebu-lifestyle
                    [URL] => 
                )

        )

)

TRASTUZUMAB

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1243290
                    [Title] => New drug helps people with advanced HER2-positive breast cancer live longer
                    [Summary] => 
Roche announced recently that trastuzumab emtansine significantly extended the time people with advanced HER2-positive breast cancer (metastatic and unresectable locally advanced/recurrent) lived without their disease worsening (progression-free survival), compared to people who received a treatment of their physician’s choice in an open-label phase III study called TH3RESA.

	 

                    [DatePublished] => 2013-10-10 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 551569
                    [Title] => Greater chances of cure for patients with breast cancer
                    [Summary] => 
Roche announced recently its new long-term follow up-data from two large pivotal studies evaluating adjuvant trastuzumab in HER2-positive early- stage breast cancer presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). 
                    [DatePublished] => 2010-02-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Freeman Cebu Lifestyle
                    [SectionUrl] => cebu-lifestyle
                    [URL] => 
                )

        )

)

abtest

New drug helps people with advanced HER2-positive breast cancer live longer

October 10, 2013 - 12:00am

Roche announced recently that trastuzumab emtansine significantly extended the time people with advanced HER2-positive breast cancer (metastatic and unresectable locally advanced/recurrent) lived without their disease...

Science and Environment

Greater chances of cure for patients with breast cancer

February 22, 2010 - 12:00am

Roche announced recently its new long-term follow up-data from two large pivotal studies evaluating adjuvant trastuzumab in HER2-positive early- stage breast cancer presented at the CTRC-AACR San Antonio Breast Cancer...

Freeman Cebu Lifestyle